Beyond Celiac Investments backs Tolerance Bio's thymus-based approach to celiac disease
What's the deal? Beyond CeliacDealroom has a profile for this one. Try Dealroom → Investments (BCI) has invested in Tolerance Bio, a biopharmaceutical startup developing a new approach to treating celiac disease.
The funding supports Tolerance Bio's celiac programme through early development and preclinical proof of concept. BCI is the venture philanthropy arm of Beyond Celiac, a nonprofit focused on accelerating treatments and a cure.
Tolerance Bio targets the thymus — the body's central regulator of immune function — to restore immune tolerance. Rather than managing symptoms, it aims to retrain the immune system at the root.
Why now? This is BCI's second investment as it builds a portfolio of preclinical and clinical-stage programmes.
Celiac disease is the only autoimmune condition with a known trigger, making it a strong candidate for a tolerising approach. "BCI's investment will help accelerate its path to the clinic," said Jordan Dubow, chief medical officer at Beyond Celiac.
What could go wrong? The science remains early. Preclinical programmes face long odds, and retraining the immune system by targeting the thymus is unproven in humans.
Tolerance Bio's pipeline spans monoclonal antibodies, cell therapies, and mRNA approaches — each a complex, costly route to the clinic with no guarantee of success.
The signal: By backing a thymus-focused platform at the preclinical stage, BCI is doubling down on a science-based venture philanthropy model that few traditional investors would touch this early. If the breakout-stage startup's tolerising approach proves out, the payoff could stretch well beyond celiac into a broader class of autoimmune therapies.
Read more: nasdaq.einnews.com
